Your browser doesn't support javascript.
loading
A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice.
Willett, Rose A; Tryndyak, Volodymyr P; Hughes Hanks, Jennifer M; Elkins, Lana; Nagumalli, Suresh K; Avigan, Mark I; Ross, Sharon A; da Costa, Gonçalo Gamboa; Beland, Frederick A; Rusyn, Ivan; Pogribny, Igor P.
Afiliação
  • Willett RA; Division of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
  • Tryndyak VP; Division of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
  • Hughes Hanks JM; Toxicologic Pathology Associates, Jefferson, AR, USA.
  • Elkins L; Toxicologic Pathology Associates, Jefferson, AR, USA.
  • Nagumalli SK; Division of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
  • Avigan MI; Office of Pharmacovigilance and Epidemiology, FDA-Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Ross SA; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
  • da Costa GG; Office of the Director, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
  • Beland FA; Division of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
  • Rusyn I; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
  • Pogribny IP; Division of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA. Electronic address: igor.pogribny@fda.hhs.gov.
Toxicol Appl Pharmacol ; : 117046, 2024 Jul 29.
Article em En | MEDLINE | ID: mdl-39084266
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease, affecting 32% of adults globally. If left untreated, NAFLD may progress to more advanced forms of the disease, including non-alcoholic steatohepatitis (NASH), liver cirrhosis, and fibrosis. Early NAFLD detection is critical to prevent disease progression. Using an obesogenic high-fat and high-sucrose (HF/HS) diet, we characterized the progression of NAFLD in male and female Collaborative Cross CC042 mice at 20-, 40-, and 60-week intervals of chronic HF/HS diet feeding. The incidence and severity of liver steatosis, inflammation, and fibrosis increased in both sexes over time, with male mice progressing to a NASH-like disease state faster than female mice, as indicated by earlier and more pronounced changes in liver steatosis. Histopathological indication of macrovesicular steatosis and gene expression changes of key lipid metabolism genes were found to be elevated in both sexes after 20 weeks of HF/HS diet. Measurement of circulating markers of inflammation (CXCL10 and TNF-α), histopathological analysis of immune cell infiltrates, and gene expression changes in inflammation-related genes indicated significant liver inflammation after 40 and 60 weeks of HF/HS diet exposure in both sexes. Liver fibrosis, as assessed by Picosirius red and Masson's trichrome staining and changes in expression of key fibrosis related genes indicated significant changes after 40 and 60 weeks of HF/HS diet exposure. In conclusion, we present a preclinical animal model of dietary NAFLD progression, which recapitulates human pathophysiological and pathomorphological changes, that could be used to better understand the progression of NAFLD and support development of new therapeutics.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Toxicol Appl Pharmacol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Toxicol Appl Pharmacol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos